For research use only. Not for therapeutic Use.
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents[1].
| Catalog Number | I043752 |
| CAS Number | 915296-00-3 |
| Purity | ≥95% |
| Reference | [1]. Magen H, et al. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. Ther Adv Hematol. 2016;7(4):187-195. |
